SCHEMBL16078941

SCHEMBL16078941

N=C1CCCN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 14/20 0.56
SIGMAR1 Q99720 14/20 0.56
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
CYP2C19 P33261 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.49
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CHRM4 P08173 1/20 0.47
HTR1A P08908 1/20 0.47
CHRM5 P08912 1/20 0.47
ADRA2A P08913 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2440342 0.84 TMEM97 (0.57) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL8323054 0.83 TMEM97 (0.56) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL7424105 0.82 MEN1 (0.71) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL1000788 0.82 MEN1 (0.71) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL5109854 0.82 MEN1 (0.71) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL3602428 0.81 MEN1 (0.62) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL6663500 0.81 TMEM97 (0.56) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL13784680 0.81 MEN1 (0.56) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL30793400 0.81 TMEM97 (0.54) TMEM97SIGMAR1MEN1KMT2ANPSR1
SCHEMBL30793327 0.81 TMEM97 (0.54) TMEM97SIGMAR1MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150376193-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT JANSSEN PHARMACEUTICA NV (BE) 2015-12-31 US disclosed
US-9156847-B2 Processes and intermediates for preparing a medicament JANSSEN PHARMACEUTICA NV (BE) 2015-10-13 US disclosed
US-20140275126-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT JANSSEN PHARMACEUTICA NV (BE) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376193-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT BTK, SYK, JAK2 TMEM97 2630/4885SIGMAR1 2212/4885MEN1 835/4885
US-20140275126-A1 PROCESSES AND INTERMEDIATES FOR PREPARING A MEDICAMENT BTK, SYK, JAK2 TMEM97 2630/4885SIGMAR1 2212/4885MEN1 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.